SG11202005822PA - Therapeutic agent for nervous system disease - Google Patents
Therapeutic agent for nervous system diseaseInfo
- Publication number
- SG11202005822PA SG11202005822PA SG11202005822PA SG11202005822PA SG11202005822PA SG 11202005822P A SG11202005822P A SG 11202005822PA SG 11202005822P A SG11202005822P A SG 11202005822PA SG 11202005822P A SG11202005822P A SG 11202005822PA SG 11202005822P A SG11202005822P A SG 11202005822PA
- Authority
- SG
- Singapore
- Prior art keywords
- therapeutic agent
- nervous system
- system disease
- disease
- nervous
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017245133 | 2017-12-21 | ||
| JP2018156503 | 2018-08-23 | ||
| PCT/JP2018/046945 WO2019124483A1 (en) | 2017-12-21 | 2018-12-20 | Agent for treatment of nervous system disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202005822PA true SG11202005822PA (en) | 2020-07-29 |
Family
ID=66993523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202005822PA SG11202005822PA (en) | 2017-12-21 | 2018-12-20 | Therapeutic agent for nervous system disease |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11369626B2 (en) |
| EP (1) | EP3730144A4 (en) |
| JP (3) | JP6650650B2 (en) |
| KR (1) | KR102684069B1 (en) |
| CN (2) | CN111511373A (en) |
| AU (1) | AU2018390261B2 (en) |
| CA (1) | CA3086220A1 (en) |
| IL (1) | IL275479A (en) |
| SG (1) | SG11202005822PA (en) |
| TW (1) | TWI798320B (en) |
| WO (1) | WO2019124483A1 (en) |
| ZA (1) | ZA202004433B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6650650B2 (en) * | 2017-12-21 | 2020-02-19 | 国立大学法人大阪大学 | Nervous system drug |
| CN112826827A (en) * | 2021-01-24 | 2021-05-25 | 华中科技大学同济医学院附属协和医院 | Application of mecobalamin in toxic-induced myelodegeneration-like diseases |
| WO2023004235A1 (en) * | 2021-07-23 | 2023-01-26 | University Of Florida Research Foundation, Incorporated | Controlling pro-inflammatory macrophage phenotype through biofunctional hydrogel design |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3889844B2 (en) * | 1997-02-10 | 2007-03-07 | 龍兒 梶 | Amyotrophic lateral sclerosis therapeutic agent |
| US6121249A (en) * | 1998-07-01 | 2000-09-19 | Donald L. Weissman | Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins |
| CN1135973C (en) * | 1999-01-18 | 2004-01-28 | 倪荣聪 | Use of methionine composition in preparation of medicine for curin cardio-cerebral vascular diseases |
| US7226916B1 (en) | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
| CN1537009A (en) * | 2001-04-25 | 2004-10-13 | �ư�������������˾ | Method for treating or preventing functional vitamin B12 dificiency in individual and to medical compositions for use in said method |
| AU2002322275A1 (en) * | 2001-06-20 | 2003-01-08 | Mayo Foundation For Medical Education And Research | Adenosyl-cobalamin fortified compositions |
| US6951658B1 (en) * | 2003-07-08 | 2005-10-04 | Pearson Research & Development Limited | Emu-based compositions for mental well-being and method of use |
| US20050032740A1 (en) * | 2003-08-06 | 2005-02-10 | Balaji Venkataraman | Vitamin compositions for the treatment and prevention of vascular disease and dementia |
| DE102005001479A1 (en) * | 2005-01-12 | 2006-07-20 | Synavit Gmbh | Agent containing folic acid, vitamin B6 and vitamin B12, and its use |
| US20070178141A1 (en) * | 2005-09-07 | 2007-08-02 | Bebaas, Inc. | Vitamin B12 compositions |
| GB0723972D0 (en) * | 2007-12-07 | 2008-01-23 | Queen Mary & Westfield College | Use of vitamin B12 |
| KR20110136826A (en) | 2009-03-26 | 2011-12-21 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | Novel therapeutic agent for cognitive impairment |
| WO2011043136A1 (en) | 2009-10-08 | 2011-04-14 | 国立大学法人名古屋大学 | Immunosuppressing agent comprising mesenchymal stem cell derived from adipose tissue, and use thereof |
| KR20130008594A (en) | 2010-03-26 | 2013-01-22 | 고쿠리츠 다이가쿠 호우징 나고야 다이가쿠 | Composition for treatment of damaged part |
| US20130143812A1 (en) | 2010-05-27 | 2013-06-06 | Sekisui Medical Co., Ltd. | Anti-inflammatory drug |
| WO2012125020A1 (en) | 2011-03-14 | 2012-09-20 | N.V. Nutricia | Method for treating neurotrauma |
| CN102631667B (en) * | 2012-04-19 | 2013-10-02 | 赵廷宝 | Nerve regeneration promotion injection and preparation method thereof |
| CN102772407B (en) * | 2012-08-01 | 2014-09-17 | 岳茂兴 | Pharmaceutical composition for promoting nerve damage restoration and application thereof |
| AU2014239651A1 (en) | 2013-03-14 | 2015-10-15 | Pharmaceutical Productions Inc. | Method of treating vitamin B12 deficiency |
| US10130657B2 (en) * | 2015-02-13 | 2018-11-20 | John C. Hughes | Formulation, apparatus, and methods for treatment of brain trauma |
| CN104688763A (en) * | 2015-03-11 | 2015-06-10 | 刘力 | Lysine-vitamin pharmaceutical composition containing chiral isocompounds and use thereof |
| ES2946262T3 (en) * | 2016-03-07 | 2023-07-14 | Univ Osaka | Sustained release drug sheet for the treatment of nerve injury |
| CN107595875B (en) * | 2016-07-12 | 2020-10-30 | 石药集团恩必普药业有限公司 | Composition containing butylphthalide and application thereof in drugs for treating cerebrovascular diseases |
| CN107595874B (en) * | 2016-07-12 | 2020-10-30 | 石药集团恩必普药业有限公司 | Pharmaceutical composition containing butylphthalide and application thereof in preparation of drugs treating cerebrovascular diseases |
| CN106107388A (en) * | 2016-07-31 | 2016-11-16 | 合肥远志医药科技开发有限公司 | A kind of Herba Lophatheri chrythanthemum beverage and preparation method thereof |
| JP6650650B2 (en) * | 2017-12-21 | 2020-02-19 | 国立大学法人大阪大学 | Nervous system drug |
-
2018
- 2018-12-20 JP JP2019554940A patent/JP6650650B2/en active Active
- 2018-12-20 WO PCT/JP2018/046945 patent/WO2019124483A1/en unknown
- 2018-12-20 TW TW107146170A patent/TWI798320B/en active
- 2018-12-20 KR KR1020207020640A patent/KR102684069B1/en active IP Right Grant
- 2018-12-20 SG SG11202005822PA patent/SG11202005822PA/en unknown
- 2018-12-20 CN CN201880082317.0A patent/CN111511373A/en active Pending
- 2018-12-20 AU AU2018390261A patent/AU2018390261B2/en active Active
- 2018-12-20 EP EP18892293.4A patent/EP3730144A4/en active Pending
- 2018-12-20 CA CA3086220A patent/CA3086220A1/en active Pending
- 2018-12-20 CN CN202410495481.1A patent/CN118403069A/en active Pending
-
2020
- 2020-01-16 JP JP2020004921A patent/JP6708869B2/en active Active
- 2020-04-07 JP JP2020068950A patent/JP6763533B2/en active Active
- 2020-06-17 IL IL275479A patent/IL275479A/en unknown
- 2020-06-22 US US16/907,913 patent/US11369626B2/en active Active
- 2020-07-17 ZA ZA2020/04433A patent/ZA202004433B/en unknown
-
2022
- 2022-05-19 US US17/748,553 patent/US11679122B2/en active Active
-
2023
- 2023-05-04 US US18/143,370 patent/US12029751B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2019124483A1 (en) | 2019-12-26 |
| WO2019124483A1 (en) | 2019-06-27 |
| US11679122B2 (en) | 2023-06-20 |
| US20220273692A1 (en) | 2022-09-01 |
| RU2020123957A (en) | 2022-01-26 |
| KR102684069B1 (en) | 2024-07-12 |
| JP6708869B2 (en) | 2020-06-10 |
| AU2018390261A1 (en) | 2020-08-06 |
| JP2020075931A (en) | 2020-05-21 |
| US11369626B2 (en) | 2022-06-28 |
| US12029751B2 (en) | 2024-07-09 |
| EP3730144A1 (en) | 2020-10-28 |
| IL275479A (en) | 2020-08-31 |
| TW201929871A (en) | 2019-08-01 |
| JP6763533B2 (en) | 2020-09-30 |
| AU2018390261B2 (en) | 2023-03-16 |
| TWI798320B (en) | 2023-04-11 |
| CA3086220A1 (en) | 2019-06-27 |
| JP2020117529A (en) | 2020-08-06 |
| CN118403069A (en) | 2024-07-30 |
| US20210008092A1 (en) | 2021-01-14 |
| EP3730144A4 (en) | 2021-09-01 |
| JP6650650B2 (en) | 2020-02-19 |
| CN111511373A (en) | 2020-08-07 |
| KR20200101948A (en) | 2020-08-28 |
| ZA202004433B (en) | 2022-01-26 |
| US20230302040A1 (en) | 2023-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201709456D0 (en) | Therapeutic agents | |
| LT3416631T (en) | Therapeutic agents for neurodegenerative diseases | |
| GB201603104D0 (en) | Therapeutic agents | |
| IL263188B (en) | Treatment for parkinson's disease | |
| ZA202004433B (en) | Therapeutic agent for nervous system disease | |
| GB201716942D0 (en) | Therapeutic compounds | |
| IL281869A (en) | Therapeutic agent for neurodegenerative disease | |
| IL273929A (en) | Therapeutic agents for neurodegenerative diseases | |
| GB201700553D0 (en) | Therapeutic agents | |
| EP3451983C0 (en) | System for neuroprotective therapy for glaucoma | |
| SG11201705915VA (en) | Therapeutic agent for ischemic diseases | |
| IL257740A (en) | Therapeutic compounds for pain and synthesis thereof | |
| ZA201807944B (en) | Treatment for parkinson's disease | |
| GB201712394D0 (en) | Therapeutic compounds | |
| GB201712395D0 (en) | Therapeutic compounds | |
| GB201712388D0 (en) | Therapeutic compounds | |
| GB201712392D0 (en) | Therapeutic compounds | |
| GB201712390D0 (en) | Therapeutic compounds | |
| GB201712393D0 (en) | Therapeutic compounds | |
| HU5050U (en) | System for thermotherapy | |
| GB201702921D0 (en) | Therapeutic agent | |
| GB201702052D0 (en) | Therapeutic agents | |
| GB201702047D0 (en) | Therapeutic agents | |
| GB201701631D0 (en) | Therapeutic agents | |
| GB201701570D0 (en) | Therapeutic agents |